Cargando…
An evaluation of the tumour endothelial marker CLEC14A as a therapeutic target in solid tumours
Earlier studies identified the transmembrane cell surface C‐type lectin CLEC14A as a putative tumour endothelial marker. For CLEC14A to progress as a vascular target in solid tumours an in‐depth analysis of CLEC14A expression in human healthy and tumour tissue is needed. It is here shown that an ana...
Autores principales: | Robinson, Joseph, Whitworth, Katharine, Jinks, Elizabeth, Nagy, Zsuzsanna, Bicknell, Roy, Lee, Steven P |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley & Sons, Inc.
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7578301/ https://www.ncbi.nlm.nih.gov/pubmed/32696621 http://dx.doi.org/10.1002/cjp2.176 |
Ejemplares similares
-
CAR T cells targeting tumor endothelial marker CLEC14A inhibit tumor growth
por: Zhuang, Xiaodong, et al.
Publicado: (2020) -
Blocking CLEC14A-MMRN2 binding inhibits sprouting angiogenesis and tumour growth
por: PJ, Noy, et al.
Publicado: (2015) -
Glutamate dependent NMDA receptor 2D is a novel angiogenic tumour endothelial marker in colorectal cancer
por: Ferguson, Henry J.M., et al.
Publicado: (2016) -
TEM8/ANTXR1-specific CAR T cells mediate toxicity in vivo
por: Petrovic, Kristina, et al.
Publicado: (2019) -
Multimerin-2 is a ligand for group 14 family C-type lectins CLEC14A, CD93 and CD248 spanning the endothelial pericyte interface
por: Khan, K A, et al.
Publicado: (2017)